Showing results (81-90 of 117) with videos related to

Sort By:
Pageof 12
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 29, 2018
Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow TransplantationKeith M Sullivan, Navneet S Majhail, Christopher Bredeson, et al.
Blood Advances|May 3, 2019
Antirelapse effect of pretransplant exposure to rabbit antithymocyte globulinRosy Dabas, Kareem Jamani, Shahbal B Kangarloo, et al.
Cytotherapy|September 3, 2022
Incomplete chimerism following myeloablative and anti-thymocyte globulin-conditioned hematopoietic cell transplantation is a risk factor for relapse and chronic graft-versus-host diseaseRutvij A Khanolkar, Gaurav Tripathi, Poonam Dharmani-Khan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 23, 2009
Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant researchVikas Gupta, Marcie Tomblyn, Tanya L Pedersen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 11, 2009
Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trialHirohisa Nakamae, Barry E Storer, Rainer Storb, et al.
Immunology and Cell Biology|March 18, 2017
MS4A4A: a novel cell surface marker for M2 macrophages and plasma cellsRatna Sanyal, Maria J Polyak, Jonathan Zuccolo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2008
Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk diseaseJames A Russell, Qiuli Duan, M Ahsan Chaudhry, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 2, 2009
The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemiaJames A Russell, William Irish, Alexander Balogh, et al.
Bone Marrow Transplantation|October 21, 2023
Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapyGérard Socié, Pere Barba, Arie Barlev, et al.
Cytotherapy|September 19, 2012
Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantationMark Bosch, Manveer Dhadda, Mette Hoegh-Petersen, et al.
Pageof 12